Cargando…

P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE

Detalles Bibliográficos
Autores principales:	Morè, S., Offidani, M., Corvatta, L., Manieri, V.M., Olivieri, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171557/ http://dx.doi.org/10.1097/01.HS9.0000936316.10252.cd

Ejemplares similares

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

P912: ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION
por: More’, Sonia, et al.
Publicado: (2023)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

Novel Experimental Drugs for Treatment of Multiple Myeloma
por: Offidani, Massimo, et al.
Publicado: (2021)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2022)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
por: Fonseca, Rafael, et al.
Publicado: (2020)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
por: Tang, Wenjiao, et al.
Publicado: (2023)

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
por: Offidani, Massimo, et al.
Publicado: (2014)

COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre()
por: Fusco, Flavia, et al.
Publicado: (2021)

Real-world treatment attrition rates in advanced esophagogastric cancer
por: Tsang, Erica S, et al.
Publicado: (2020)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Metaplastic carcinoma of the breast: real-world outcome from a tertiary cancer centre in India
por: Balasubramanian, Ananthi, et al.
Publicado: (2022)

Immunophenotypic Profile of Multiple Myeloma: A Tertiary Care Centre Experience
por: Rath, Asish, et al.
Publicado: (2023)

47th Scientific Meeting of the Italian Statistical Society
por: Battista, Tonio, et al.
Publicado: (2016)

The Importance of Endoscopy with Biopsy: Real-World Evidence of Gastrointestinal Involvement in Primary Immunodeficiency in Two Main Northern Italian Centres
por: Nicola, Stefania, et al.
Publicado: (2023)

The Law of Attrition
por: Eysenbach, Gunther
Publicado: (2005)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021)

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
por: Kreeshan, Firas Constantin, et al.
Publicado: (2020)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
por: Richter, Joshua, et al.
Publicado: (2023)

P978: EVOLVING PATTERNS IN MULTIPLE MYELOMA TREATMENT ATTRITION RATES AND PROGRESSION THROUGH LINES OF THERAPY WITH MODERN CHEMOTHERAPY OPTIONS
por: Al-Kaisi, Firas, et al.
Publicado: (2023)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Fuchs' Heterochromic Iridocyclitis in an Italian Tertiary Referral Centre: Epidemiology, Clinical Features, and Prognosis
por: Accorinti, Massimo, et al.
Publicado: (2016)

Real world perspective of coronary chronic total occlusion in third world countries: A tertiary care centre study from northern India
por: Vemuri, Krishna Santosh, et al.
Publicado: (2021)

Periodontitis and the subsequent risk of glaucoma: results from the real-world practice
por: Sun, Kuo-Ting, et al.
Publicado: (2020)

Periodontitis and Subsequent Risk of Cataract: Results From Real-World Practice
por: Yeh, Li-Jen, et al.
Publicado: (2022)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3cl53f6uj1qeicgivdglfs8kot